The recently announced acquisition of Finjan Holdings, Inc. (NASDAQ: FNJN), a cybersecurity and patent licensing firm, by Fortress Investment Group, a division of SoftBank, is being
The recently announced acquisition of Finjan Holdings, Inc. (NASDAQ: FNJN), a cybersecurity and patent licensing firm, by Fortress Investment Group, a division of SoftBank, is being
A Chinese court ordered a Shenzhen company to pay three million yuan ($430,000 USD) each in two lawsuits filed by MGM Holdings for trademark infringement
Intellectual property is the domain of every student, not just those studying law. That’s the conclusion reached by Phil Hearne, Director of Education for the
This week IPwe, the company headed by former patent litigation king Erich Spangenberg, acquired ClearAccess IP, a venture-backed, Palo Alto-based IP analytics company associated through
A newly released video featuring conversations with leading intellectual property practitioners, professionals and creators stresses the need to assure the role of IP rights is
A recent United States Supreme Court ruling involving a video about diving for sunken treasure that depicted the recovery of artifacts from Blackbeard’s 18th century
Johnson & Johnson, the pharmaceutical giant, said yesterday it is five months away from starting human trials on a COVID-19 vaccine that would be offered
A veteran venture capitalist and technology investor is calling for Congress to revise the patent laws and for companies to step up and embrace their
Is it possible to copyright every possible melody? A lawyer says he has and that it is good for musicians and the music industry. Not
Top-Fifty member of the Fortune’s “World’s Greatest Leaders,” Arunachalam Muruganantham, inventor of an inexpensive machine that make sanitary pads for women, says students need to
While the U.S. still remains the top nation overall for intellectual property rights, lags behind Singapore, Japan, South Korea and Switzerland in the category Patents,
An attempt to patent a medicine already patented in the U.S. and elsewhere, and currently being developed by U.S. drugmaker Gilead Sciences, raises serious intellectual